Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 13Active not recruiting 5Not yet recruiting 2Completed 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lymphatic Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 21Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Radiotherapy 10Doxorubicin 10Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Injections 7Etoposide 7Leucovorin 6Ipilimumab 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Radiosurgery 5Prednisone 5Pemetrexed 5Methotrexate 5Dexamethasone 5Cetuximab 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Surgical Procedures, Operative × 30 days × Clear all
NCT03924856 2026-05-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Completed
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02364557 2026-05-19

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NRG Oncology

Phase 2/3 Completed
129 enrolled 23 charts
Breast

Breast Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡